Media coverage about Protagonist Therapeutics (NASDAQ:PTGX) has been trending somewhat negative this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Protagonist Therapeutics earned a coverage optimism score of -0.07 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.0152135042635 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
NASDAQ:PTGX traded down $0.01 during trading hours on Friday, reaching $6.85. The stock had a trading volume of 1,290,500 shares, compared to its average volume of 229,463. Protagonist Therapeutics has a 12-month low of $5.50 and a 12-month high of $23.97. The company has a market capitalization of $150.34 million, a P/E ratio of -3.28 and a beta of 3.28.
Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Wednesday, May 9th. The company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.07). The firm had revenue of $10.78 million during the quarter, compared to the consensus estimate of $10.70 million. analysts forecast that Protagonist Therapeutics will post -0.98 EPS for the current year.
A number of analysts have issued reports on the company. Zacks Investment Research downgraded Protagonist Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 29th. BMO Capital Markets reissued an “outperform” rating and issued a $13.00 target price (down from $42.00) on shares of Protagonist Therapeutics in a research report on Monday, March 26th. They noted that the move was a valuation call. BidaskClub raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 3rd. Stifel Nicolaus downgraded Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, March 26th. Finally, Barclays downgraded Protagonist Therapeutics from an “overweight” rating to an “equal weight” rating and set a $18.00 target price for the company. in a research report on Wednesday, June 6th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $25.00.
In other news, major shareholder X L.P. Canaan sold 77,591 shares of Protagonist Therapeutics stock in a transaction on Monday, May 14th. The stock was sold at an average price of $6.37, for a total value of $494,254.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bryan Giraudo purchased 10,000 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, May 16th. The stock was bought at an average price of $6.46 per share, with a total value of $64,600.00. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $64,600. The disclosure for this purchase can be found here. 13.80% of the stock is currently owned by insiders.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.